NasdaqGS:COGTBiotechs
A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA
FDA acceptance of bezuclastinib NDA puts Cogent Biosciences in focus
Cogent Biosciences (COGT) is back on investors' radar after the FDA accepted its New Drug Application for bezuclastinib in Gastrointestinal Stromal Tumors under the Real-Time Oncology Review program.
The filing follows results from the Phase 3 PEAK trial, in which bezuclastinib combined with sunitinib reduced the risk of disease progression or death by 50% compared with sunitinib alone and received Breakthrough Therapy...